Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies

Eli Lilly And Co LLY is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to develop new therapies for metabolic disorders.

• Under the deal, Lilly will have a license to select Regor IP with an option to extend the license. 
• Lilly will be responsible for clinical development, manufacturing, and commercialization worldwide except China, Macau, Hong Kong, and Taiwan, where Regor will maintain these rights and responsibilities.
• Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor. 
• The Company is also eligible to receive up to $1.5 billion in potential milestone payments and tiered royalties from low-single to low-double digits.
• Also Read: Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns.
• Price Action: LLY shares are up 0.45% at $244.00 during the premarket session on the last check Friday.